Agilysys, Inc. (AGYS) Forms $12.25 Double Top; New Leaf Venture Partners Lowered Its Oxford Immunotec Global Plc (OXFD) Position

New Leaf Venture Partners Llc decreased Oxford Immunotec Global Plc (OXFD) stake by 10.5% reported in 2017Q3 SEC filing. New Leaf Venture Partners Llc sold 100,000 shares as Oxford Immunotec Global Plc (OXFD)’s stock rose 4.03%. The New Leaf Venture Partners Llc holds 852,497 shares with $14.32 million value, down from 952,497 last quarter. Oxford Immunotec Global Plc now has $295.29M valuation. The stock increased 3.14% or $0.35 during the last trading session, reaching $11.51. About 279,280 shares traded or 43.91% up from the average. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since January 11, 2017 and is uptrending. It has outperformed by 37.56% the S&P500.

Agilysys, Inc. (AGYS) formed double top with $12.99 target or 6.00% above today’s $12.25 share price. Agilysys, Inc. (AGYS) has $285.65M valuation. The stock increased 0.57% or $0.07 during the last trading session, reaching $12.25. About 34,307 shares traded. Agilysys, Inc. (NASDAQ:AGYS) has declined 6.49% since January 11, 2017 and is downtrending. It has underperformed by 23.19% the S&P500.

Investors sentiment decreased to 1.13 in 2017 Q3. Its down 0.14, from 1.27 in 2017Q2. It fall, as 3 investors sold OXFD shares while 27 reduced holdings. 12 funds opened positions while 22 raised stakes. 22.51 million shares or 13.08% more from 19.91 million shares in 2017Q2 were reported. Price T Rowe Assoc Incorporated Md owns 748,627 shares. Ameritas Inv reported 1,917 shares stake. Moreover, Credit Suisse Ag has 0% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 14,898 shares. Alliancebernstein Ltd Partnership reported 14,700 shares. Tiverton Asset Mngmt Ltd Co accumulated 0.17% or 175,000 shares. Fosun Intl holds 0.4% or 237,783 shares in its portfolio. C Gru A S reported 183,235 shares. Essex Investment Limited Liability Corp has invested 0.32% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Columbus Circle Investors accumulated 157,123 shares. State Bank Of America De holds 0% or 1,233 shares in its portfolio. Invesco Limited invested 0.02% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Tiaa Cref Invest Mgmt Limited Liability Company reported 84,854 shares. Spark Invest Mngmt Llc reported 0.08% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD). Rhumbline Advisers has 0% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD). Waddell & Reed Fin invested in 0.01% or 227,400 shares.

Since August 7, 2017, it had 0 insider buys, and 4 selling transactions for $1.52 million activity. $395,971 worth of Oxford Immunotec Global PLC (NASDAQ:OXFD) shares were sold by Edwardson Peter. 55,000 shares were sold by Wrighton-Smith Peter, worth $922,933 on Monday, October 2. SANDBERG RICHARD A sold $47,460 worth of stock.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on February, 27. They expect $-0.36 earnings per share, down 63.64% or $0.14 from last year’s $-0.22 per share. After $-0.24 actual earnings per share reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 9 analyst reports since July 19, 2017 according to SRatingsIntel. The rating was maintained by Cowen & Co with “Buy” on Wednesday, September 27. Robert W. Baird maintained the stock with “Buy” rating in Tuesday, October 31 report. Robert W. Baird maintained it with “Buy” rating and $22.0 target in Thursday, October 19 report. Cowen & Co maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Tuesday, October 31. Cowen & Co has “Buy” rating and $19.0 target. BTIG Research initiated the stock with “Buy” rating in Thursday, September 28 report. The stock has “Buy” rating by Piper Jaffray on Monday, January 8. Cowen & Co maintained the shares of OXFD in report on Wednesday, July 19 with “Buy” rating. Cowen & Co maintained Oxford Immunotec Global PLC (NASDAQ:OXFD) rating on Wednesday, August 16. Cowen & Co has “Buy” rating and $19.0 target.